Medroxyprogesterone instructions for administration: Difference between revisions
No edit summary |
(No difference)
|
Revision as of 06:26, 20 December 2011
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overdosage topics
Vasomotor Symptoms / Vulvar and Vaginal Atrophy
Postmenopausal Osteoporosis
Vasomotor Symptoms / Vulvar and Vaginal Atrophy
Patients should be treated with the lowest effective dose. Generally women should be started at
0.3 mg/1.5 mg PREMPRO daily. Subsequent dosage adjustment may be made based upon the
individual patient response. In patients where bleeding or spotting remains a problem, after appropriate
evaluation, consideration should be given to changing the dose level. This dose should be periodically
reassessed by the healthcare provider.
Postmenopausal Osteoporosis
Patients should be treated with the lowest effective dose. Generally women should be started at
0.3 mg/1.5 mg PREMPRO daily. Dosage may be adjusted depending on individual clinical and bone
mineral density responses. This dose should be periodically reassessed by the healthcare provider.
In patients where bleeding or spotting remains a problem, after appropriate evaluation, consideration
should be given to changing the dose level. This dose should be periodically reassessed by the
healthcare provider.
PREMPHASE therapy consists of two separate tablets; one maroon 0.625 mg Premarin tablet taken
daily on days 1 through 14 and one light-blue tablet, containing 0.625 mg conjugated estrogens and
5 mg of medroxyprogesterone acetate, taken on days 15 through 28.
Adapted from the FDA Package Insert.